Last reviewed · How we verify

sitagliptin and acarbose — Competitive Intelligence Brief

sitagliptin and acarbose (sitagliptin and acarbose) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: DPP-4 inhibitor + alpha-glucosidase inhibitor combination. Area: Diabetes.

marketed DPP-4 inhibitor + alpha-glucosidase inhibitor combination DPP-4 enzyme; alpha-glucosidase enzymes Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

sitagliptin and acarbose (sitagliptin and acarbose) — Nanjing First Hospital, Nanjing Medical University. This combination reduces blood glucose by inhibiting dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and slowing carbohydrate digestion via alpha-glucosidase inhibition.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
sitagliptin and acarbose TARGET sitagliptin and acarbose Nanjing First Hospital, Nanjing Medical University marketed DPP-4 inhibitor + alpha-glucosidase inhibitor combination DPP-4 enzyme; alpha-glucosidase enzymes

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (DPP-4 inhibitor + alpha-glucosidase inhibitor combination class)

  1. Nanjing First Hospital, Nanjing Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). sitagliptin and acarbose — Competitive Intelligence Brief. https://druglandscape.com/ci/sitagliptin-and-acarbose. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: